List view / Grid view
7 July 2016 | By Victoria White, Digital Content Producer
Nearly half of adult patients treated with Humira achieved at least a 75% improvement in their fingernail psoriasis compared to patients receiving placebo...
7 July 2016 | By Victoria White, Digital Content Producer
The EC has granted an extension of the Market Authorisation for Revestive for the treatment of patients aged one year and above with Short Bowel Syndrome...
7 July 2016 | By Victoria White, Digital Content Producer
The EGALITY study involved 531 patients and compared the efficacy and safety of biosimilar etanercept with the originator product, Enbrel...
7 July 2016 | By Victoria White, Digital Content Producer
Bosutinib is the first drug to go through the reappraisal process, where NICE assesses the cost and clinical effectiveness of drugs currently in the old CDF...
7 July 2016 | By Victoria White, Digital Content Producer
In the recent Referendum, the majority voted against the UK's continued membership of the EU. Now, the EMA has issued a statement on the outcome of the vote...
6 July 2016 | By Victoria White, Digital Content Producer
The type 2 diabetes market will see companies prioritisng competitive pricing in order to offset the impact of patent expiries, says GlobalData...
6 July 2016 | By Victoria White, Digital Content Producer
Scientists have developed a cost-effective vaccine cooler which preserves vaccines for 35 days using just 30 litres of ice and without needing electricity...
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
6 July 2016 | By Victoria White, Digital Content Producer
The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma...
6 July 2016 | By Victoria White, Digital Content Producer
Scancell has provided an update from the SCIB1 Phase I/II clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody platform...
6 July 2016 | By Victoria White, Digital Content Producer
Medivation has entered into confidentiality agreements with parties that have expressed interest in exploring a potential transaction to acquire the company...
6 July 2016 | By Victoria White, Digital Content Producer
The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares...
5 July 2016 | By Victoria White, Digital Content Producer
The six-month study will enrol 60 to 120 Ebola survivors whose semen has evidence of Ebola virus RNA prior to their enrolment...
5 July 2016 | By Victoria White, Digital Content Producer
The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS...
5 July 2016 | By Victoria White, Digital Content Producer
The acquisition gives Bristol-Myers Squibb full rights to Cormorant Pharmaceuticals' HuMax-IL8 antibody programme...
